Pharmacokinetics of arsenic trioxide (As₂O₃) in Chinese primary hepatocarcinoma patients.

@article{Hua2011PharmacokineticsOA,
  title={Pharmacokinetics of arsenic trioxide (As₂O₃) in Chinese primary hepatocarcinoma patients.},
  author={Haiqing Hua and Shukui Qin and Jianzhong Rui and Jinheng Li},
  journal={Asian Pacific journal of cancer prevention : APJCP},
  year={2011},
  volume={12 1},
  pages={
          61-5
        }
}
BACKGROUND Arsenic trioxide (As₂O₃) induces growth inhibition and apoptosis in human hepatocarcinoma cell lines, but little is known about its pharmacology with this cancer in vivo. Pharmacokinetics after As₂O₃ injection into patients with a primary hepatocarcinoma (PHC) were therefore investigated. METHODS Fourteen patients were enrolled after providing informed consent and given daily intravenous doses of 10 mg for 14 days. Three mL blood samples were collected before and 1 h, 2 h, 3 h, 4 h… CONTINUE READING